To appraise the clinical and cost effectiveness of voretigene neparvovec within its marketing authorisation for treating inherited retinal dystrophies caused by RPE65 gene mutations.
Status Proposed
Process STA
ID number 1054

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
13 September 2017 (00:00) Scoping workshop
19 July 2017 - 16 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance